Evelyn Partners Group Ltd’s Teva Pharmaceuticals TEVA Stock Holding History

Evelyn Partners Group Ltd’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3K	Buy	+480	New	+$16K	﹤0.01%	457

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

TAM

Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

YDMI

Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

Evelyn Partners Group Ltd's TEVA Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 480 shares worth $16.3K. The stake represents ﹤0.01% of the portfolio and ranks #457 among its holdings.

332 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Evelyn Partners Group Ltd held 480 shares of Teva Pharmaceuticals worth $16.3K as of Q2 2026.
Teva Pharmaceuticals was a new Evelyn Partners Group Ltd position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #457 holding.
332 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.